Literature DB >> 28765941

B7-H3 is related to tumor progression in ovarian cancer.

Jingjing Zhang1, Lu Liu1, Sai Han1, Yi Li1, Qiuhong Qian1, Qianqian Zhang1, Hui Zhang2, Ziyan Yang1, Youzhong Zhang1.   

Abstract

B7-H3, a co-stimulatory molecule, has been found expressed in ovarian cancer, but its role and mechanism is not clear. In this study, we further verified the expression of B7-H3 in ovarian carcinoma and normal epithelial ovarian tissues. Three ovarian cancer cell lines, A2780, SKOV3 and HO8910 were selected to explore the effects of B7-H3 on proliferation, apoptosis, migration and invasion. We found that B7-H3 was mainly located in the cytoplasm of ovarian cancer cells as determined by immunofluorescence staining. The ability of cell invasion, migration, proliferation decreased after silencing B7-H3 whereas the apoptosis increased, which was related to the upregulation of Bax, caspase-8, cleaved caspase-8 and the downregulation of Bcl-2, Bcl-xl, matrix metalloproteinase-2 (MMP2) by western blotting. In addition, B7-H3 enhanced the H08910 cell capacities in invasion, migration and proliferation. Expression of the phosphorylation signal transducer and activator of transcription 3 (pStat3) molecules and their upstream molecules phosphorylation Janus kinase 2 (pJak2) were significantly increased. In order to investigate whether B7-H3 plays a role in this pathway, we treated the overexpressed HO8910 cells with AG490 (inhibitors of Jak2). Our findings revealed that B7-H3 affect ovarian cancer progression through the Jak2/Stat3 pathway, indicating that B7-H3 has the potential to be a useful prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765941     DOI: 10.3892/or.2017.5858

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Authors:  Phyu P Aung; Edwin Roger Parra; Souptik Barua; Dawen Sui; Jing Ning; Barbara Mino; Debora Alejandra Ledesma; Jonathan L Curry; Priyadharsini Nagarajan; Carlos A Torres-Cabala; Eleni Efstathiou; Anh G Hoang; Michael K Wong; Jennifer A Wargo; Alexander J Lazar; Arvind Rao; Victor G Prieto; Ignacio Wistuba; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2019-02-26       Impact factor: 12.531

2.  Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.

Authors:  Dongli Cai; Jiaming Li; Dingfeng Liu; Shanjuan Hong; Qin Qiao; Qinli Sun; Pingping Li; Nanan Lyu; Tiantian Sun; Shan Xie; Li Guo; Ling Ni; Liping Jin; Chen Dong
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

3.  Soluble B7-H3 in Ovarian Cancer and Its Predictive Value.

Authors:  O V Kovaleva; T P Belova; E A Korotkova; D N Kushlinskii; A N Gratchev; N A Petrikova; D A Kudlay; N E Kushlinskii
Journal:  Bull Exp Biol Med       Date:  2021-09-20       Impact factor: 0.804

4.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

5.  CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma.

Authors:  Guangxing Yue; Jingwen Tang; Lihan Zhang; Hong Niu; Huahua Li; Suxia Luo
Journal:  J Gastrointest Oncol       Date:  2021-02

Review 6.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

7.  Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3.

Authors:  Takahiro Nakagomi; Taichiro Goto; Yosuke Hirotsu; Daichi Shikata; Yujiro Yokoyama; Rumi Higuchi; Sotaro Otake; Kenji Amemiya; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Cancers (Basel)       Date:  2018-11-30       Impact factor: 6.639

Review 8.  B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.

Authors:  Shuo Yang; Wei Wei; Qi Zhao
Journal:  Int J Biol Sci       Date:  2020-03-25       Impact factor: 6.580

9.  Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.

Authors:  Cheng Huang; Hongjian Li; Yunyu Feng; Xiaoling Li; Zongliang Zhang; Caiying Jiang; Jichao Wang; Chenli Yang; Yuying Fu; Min Mu; Shasha Zhao; Zeng Wang; Yi Kuang; Huan Hou; Yuelong Wang; Wenhao Guo; Jianguo Xu; Hui Yang; Liangxue Zhou; Aiping Tong; Gang Guo
Journal:  Theranostics       Date:  2020-08-21       Impact factor: 11.556

10.  Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer.

Authors:  Qianqian Zhang; Liju Zong; Hui Zhang; Wei Xie; Fan Yang; Wenwen Sun; Baoxia Cui; Youzhong Zhang
Journal:  Onco Targets Ther       Date:  2021-07-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.